« Previous
Next »
Titles
- Aducanumab for Alzheimer’s disease: effectiveness and value1
- Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: effectiveness and value1
- Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value : final report1
- Mavacamten for hypertrophic cardiomyopathy: effectiveness and value : final evidence report and meeting summary1
- Modulator treatments for cystic fibrosis: effectiveness and value1
- Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, non-muscle invasive bladder cancer: effectiveness and value : final report1
- Supervised injection facilities and other supervised consumption sites: effectiveness and value : final report1
- Tezepelumab for severe asthma: final report1
- Treatments for anemia in chronic kidney disease: effectiveness and value : final evidence report1
- Unsupported price increase report: 2020 assessment1
- Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value : final report1